IGPK Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -- compared to Integrated Cannabis Solutions, Inc.'s net margin of 12.65%. Integrated Cannabis Solutions, Inc.'s return on equity of -- beat Electromed, Inc.'s return on equity of 18.89%.

Integrated Cannabis Solutions, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25.79%. Given that Electromed, Inc. has higher upside potential than Integrated Cannabis Solutions, Inc., analysts believe Electromed, Inc. is more attractive than Integrated Cannabis Solutions, Inc..

Integrated Cannabis Solutions, Inc. has a beta of 0.817, which suggesting that the stock is 18.314% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Integrated Cannabis Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integrated Cannabis Solutions, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Integrated Cannabis Solutions, Inc. quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Integrated Cannabis Solutions, Inc.'s net income of -- is lower than Electromed, Inc.'s net income of $2.1M. Notably, Integrated Cannabis Solutions, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integrated Cannabis Solutions, Inc. is 0.08x versus 3.82x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Venus Concept, Inc. has a net margin of -- compared to Integrated Cannabis Solutions, Inc.'s net margin of -163.68%. Integrated Cannabis Solutions, Inc.'s return on equity of -- beat Venus Concept, Inc.'s return on equity of -1236.95%.

Integrated Cannabis Solutions, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Venus Concept, Inc. has an analysts' consensus of -- which suggests that it could grow by 5972.92%. Given that Venus Concept, Inc. has higher upside potential than Integrated Cannabis Solutions, Inc., analysts believe Venus Concept, Inc. is more attractive than Integrated Cannabis Solutions, Inc..

Integrated Cannabis Solutions, Inc. has a beta of 0.817, which suggesting that the stock is 18.314% less volatile than S&P 500. In comparison Venus Concept, Inc. has a beta of -0.111, suggesting its less volatile than the S&P 500 by 111.094%.

Integrated Cannabis Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Venus Concept, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integrated Cannabis Solutions, Inc. pays -- of its earnings as a dividend. Venus Concept, Inc. pays out -- of its earnings as a dividend.

Integrated Cannabis Solutions, Inc. quarterly revenues are --, which are smaller than Venus Concept, Inc. quarterly revenues of $13.8M. Integrated Cannabis Solutions, Inc.'s net income of -- is lower than Venus Concept, Inc.'s net income of -$22.5M. Notably, Integrated Cannabis Solutions, Inc.'s price-to-earnings ratio is -- while Venus Concept, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integrated Cannabis Solutions, Inc. is 0.08x versus 0.04x for Venus Concept, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -- compared to Integrated Cannabis Solutions, Inc.'s net margin of -862.39%. Integrated Cannabis Solutions, Inc.'s return on equity of -- beat VolitionRX Ltd.'s return on equity of --.

Integrated Cannabis Solutions, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 759.38%. Given that VolitionRX Ltd. has higher upside potential than Integrated Cannabis Solutions, Inc., analysts believe VolitionRX Ltd. is more attractive than Integrated Cannabis Solutions, Inc..

Integrated Cannabis Solutions, Inc. has a beta of 0.817, which suggesting that the stock is 18.314% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Integrated Cannabis Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integrated Cannabis Solutions, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Integrated Cannabis Solutions, Inc. quarterly revenues are --, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Integrated Cannabis Solutions, Inc.'s net income of -- is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Integrated Cannabis Solutions, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integrated Cannabis Solutions, Inc. is 0.08x versus 17.54x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -- compared to Integrated Cannabis Solutions, Inc.'s net margin of 3.93%. Integrated Cannabis Solutions, Inc.'s return on equity of -- beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Integrated Cannabis Solutions, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 94.81%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Integrated Cannabis Solutions, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Integrated Cannabis Solutions, Inc..

Integrated Cannabis Solutions, Inc. has a beta of 0.817, which suggesting that the stock is 18.314% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Integrated Cannabis Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integrated Cannabis Solutions, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Integrated Cannabis Solutions, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Integrated Cannabis Solutions, Inc.'s net income of -- is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Integrated Cannabis Solutions, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 75.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integrated Cannabis Solutions, Inc. is 0.08x versus 0.84x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.